Naples Comprehensive Health is building up what it hopes will be a nationally recognized cardiology program. Robert Cubeddu, MD, and Dee Dee Wang, MD, spoke with Cardiovascular Business about the journey so far.
Aortic valve replacement is likely inevitable for patients with asymptomatic severe aortic stenosis. Immediately performing TAVR or SAVR, however, may not always be the answer.
"We wanted to ensure that every interventionalist, regardless of location or resources, has access to the best information possible," one co-author said.
Michael Reardon, MD, presents late-breaking data comparing TAVR to SAVR in low-risk patients after five years.
Michael J. Reardon, MD, shared the highly anticipated data with a large audience at ACC.25 in Chicago. Overall, he said, these five-year findings suggest TAVR with a supra-annular, self-expanding valve is a safe and effective alternative to SAVR.
Darren K. McGuire, MD, a professor of medicine at UT Southwestern Medical Center, presents late-breaking clinical data on the cardiovascular benefits of oral semaglutide during ACC.25 in Chicago.
Researchers still think patients should receive an injectable version of semaglutide when possible, but new data out of ACC.25 confirm that an oral formulation of the drug is associated with significant benefits.
Cardiologist Marc P. Bonaca, MD, presents the STRIDE late-breaking clinical trial at ACC.25 in Chicago.
Patients who present with type 2 diabetes and PAD often face substantial mobility issues. According to new data presented at ACC.25, however, treatment with semaglutide could represent a major step forward for this high-risk population.
Etripamil's journey toward FDA approval hit a roadblock. The agency requested additional information on the drug, including a new facility inspection, in a response letter sent to Milestone Pharmaceuticals.
